abstract |
The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]- hexadeca-2(11 ),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an advers e effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distributio n and potency. |